PL1615613T3 - Chinoksalinylowe makrocykliczne inhibitory proteazy serynowej zapalenia wątroby typu C - Google Patents

Chinoksalinylowe makrocykliczne inhibitory proteazy serynowej zapalenia wątroby typu C

Info

Publication number
PL1615613T3
PL1615613T3 PL04750236T PL04750236T PL1615613T3 PL 1615613 T3 PL1615613 T3 PL 1615613T3 PL 04750236 T PL04750236 T PL 04750236T PL 04750236 T PL04750236 T PL 04750236T PL 1615613 T3 PL1615613 T3 PL 1615613T3
Authority
PL
Poland
Prior art keywords
present
compounds
serine protease
hepatitis
formula
Prior art date
Application number
PL04750236T
Other languages
English (en)
Inventor
Suanne Nakajima
Ying Sun
Datong Tang
Gouyou Xu
Brian Porter
Yat Sun Or
Zhe Wang
Zhenwei Miao
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of PL1615613T3 publication Critical patent/PL1615613T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL04750236T 2003-04-18 2004-04-16 Chinoksalinylowe makrocykliczne inhibitory proteazy serynowej zapalenia wątroby typu C PL1615613T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41875903A 2003-04-18 2003-04-18
PCT/US2004/011841 WO2004093798A2 (en) 2003-04-18 2004-04-16 Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
EP04750236A EP1615613B1 (en) 2003-04-18 2004-04-16 Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors

Publications (1)

Publication Number Publication Date
PL1615613T3 true PL1615613T3 (pl) 2010-04-30

Family

ID=33309537

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04750236T PL1615613T3 (pl) 2003-04-18 2004-04-16 Chinoksalinylowe makrocykliczne inhibitory proteazy serynowej zapalenia wątroby typu C

Country Status (15)

Country Link
EP (2) EP1615613B1 (pl)
JP (2) JP4778893B2 (pl)
KR (1) KR101031825B1 (pl)
CN (1) CN1788006A (pl)
AT (1) ATE447573T1 (pl)
AU (2) AU2004231987C1 (pl)
CA (1) CA2522561C (pl)
CY (1) CY1109748T1 (pl)
DE (1) DE602004023924D1 (pl)
DK (1) DK1615613T3 (pl)
ES (2) ES2535147T3 (pl)
PL (1) PL1615613T3 (pl)
PT (1) PT1615613E (pl)
SI (1) SI1615613T1 (pl)
WO (1) WO2004093798A2 (pl)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
BRPI0414814A (pt) 2003-09-26 2006-11-14 Schering Corp inibidores macrocìclicos de protease de serina ns3 de vìrus de hepatite c
BRPI0506948B1 (pt) 2004-01-30 2018-09-18 Medivir Ab inibidores de serina protease ns-3 de hcv
EP1711515A2 (en) * 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
TWI368507B (en) 2004-02-20 2012-07-21 Boehringer Ingelheim Int Viral polymerase inhibitors
JP2008517896A (ja) * 2004-10-21 2008-05-29 ファイザー・インク Ｃ型肝炎ウイルスプロテアーゼの阻害剤並びにそれを用いた組成物及び治療
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR101294467B1 (ko) * 2005-07-25 2013-09-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
CA2618682C (en) 2005-08-12 2011-06-21 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US20070281884A1 (en) * 2006-06-06 2007-12-06 Ying Sun Macrocyclic oximyl hepatitis C protease inhibitors
UY30437A1 (es) 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2054388A4 (en) 2006-08-17 2009-10-28 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US20080107623A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2357494T3 (es) * 2006-11-16 2011-04-27 Bristol-Myers Squibb Company Péptidos macrocíclicos como inhibidores de la hepatitis c.
WO2008086161A1 (en) * 2007-01-08 2008-07-17 Phenomix Corporation Macrocyclic hepatitis c protease inhibitors
TWI395746B (zh) 2007-06-29 2013-05-11 Gilead Sciences Inc 抗病毒性化合物
CA2692145C (en) 2007-06-29 2015-03-03 Gilead Sciences, Inc. Antiviral compounds
WO2009005690A2 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
WO2009018657A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CN101977621A (zh) 2007-12-05 2011-02-16 益安药业 氟化三肽hcv丝氨酸蛋白酶抑制剂
CN103483251A (zh) 2007-12-19 2014-01-01 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
AR070413A1 (es) * 2008-02-04 2010-04-07 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de proteasa de serina
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2300491B1 (en) 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
AU2012201327B2 (en) * 2008-09-11 2014-06-26 Abbvie Ireland Unlimited Company Macrocyclic hepatitis C serine protease inhibitors
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2010203656A1 (en) 2009-01-07 2011-07-21 Scynexis, Inc. Cyclosporine derivative for use in the treatment of HCV and HIV infection
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
MX2011012155A (es) 2009-05-13 2012-02-28 Enanta Pharm Inc Compuestos macrociclicos como inhibidores del virus de hepatitis c.
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
CN105001302A (zh) * 2009-09-28 2015-10-28 英特穆恩公司 C型肝炎病毒复制的环肽抑制剂
BR112013006693B1 (pt) 2010-09-21 2022-07-12 Enanta Pharmaceuticals, Inc Compostos inibidores da serino protease hcv derivada de prolina macrocíclica
WO2012054874A1 (en) * 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2943496B1 (en) * 2013-01-10 2017-09-06 Bristol-Myers Squibb Company Macrocyclic benzofuran and azabenzofuran compounds for the treatment of hepatitis c
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP3391898A3 (en) * 2013-03-13 2019-02-13 President and Fellows of Harvard College Stapled and stitched polypeptides and uses thereof
CN105073758B (zh) 2013-03-15 2017-08-11 吉利德科学公司 丙型肝炎病毒抑制剂
MX2015017274A (es) 2013-06-14 2016-08-04 Harvard College Moduladores del receptor del polipéptido insulina estabilizados.
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
EP3782636B1 (en) 2016-02-04 2024-05-15 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
US11708391B2 (en) 2016-02-04 2023-07-25 The Johns Hopkins University Rapaglutins, novel inhibitors of GLUT and use thereof
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
MX2020002435A (es) 2017-09-07 2020-09-22 Fog Pharmaceuticals Inc Agentes que modulan las funciones de beta-catenina y sus métodos.
US20220372014A1 (en) * 2019-10-01 2022-11-24 The Johns Hopkins University Neuroprotective compounds and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2265512A1 (en) * 1996-09-27 1998-04-02 Merck & Co., Inc. Detergent-free hepatitis c protease
US5861297A (en) 1996-09-27 1999-01-19 Merck & Co., Inc. Detergent-free hepatitis C protease
DK1003775T3 (da) 1997-08-11 2005-05-30 Boehringer Ingelheim Ca Ltd Hepatitis C-inhibitorpeptider
EP1066247B1 (en) 1998-03-31 2006-11-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6086469A (en) * 1998-10-29 2000-07-11 Dec International, Inc. Method and means for conveying and processing an extruded sausage strand
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition

Also Published As

Publication number Publication date
DE602004023924D1 (en) 2009-12-17
ATE447573T1 (de) 2009-11-15
AU2004231987C1 (en) 2010-09-30
JP2007525455A (ja) 2007-09-06
JP2011178781A (ja) 2011-09-15
WO2004093798A3 (en) 2005-12-08
EP1615613A2 (en) 2006-01-18
CY1109748T1 (el) 2014-09-10
PT1615613E (pt) 2010-02-09
AU2004231987A1 (en) 2004-11-04
WO2004093798A2 (en) 2004-11-04
AU2010200619B2 (en) 2013-11-07
CA2522561C (en) 2012-07-17
HK1140214A1 (en) 2010-10-08
EP1615613A4 (en) 2007-02-14
HK1083337A1 (en) 2006-06-30
AU2010200619A1 (en) 2010-03-11
CN1788006A (zh) 2006-06-14
EP1615613B1 (en) 2009-11-04
SI1615613T1 (sl) 2010-03-31
CA2522561A1 (en) 2004-11-04
EP2143727A1 (en) 2010-01-13
ES2535147T3 (es) 2015-05-06
JP4778893B2 (ja) 2011-09-21
EP2143727B1 (en) 2015-01-21
KR101031825B1 (ko) 2011-04-29
DK1615613T3 (da) 2010-03-22
KR20050123170A (ko) 2005-12-29
ES2335887T3 (es) 2010-04-06
AU2004231987B2 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
SI1615613T1 (sl) Kinoksalinilni makrociklični inhibitorji serinske proteaze hepatitisa C
WO2004113365A3 (en) Hepatitis c serine protease tri-peptide inhibitors
WO2008002924A3 (en) Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2005007681A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2004072243A3 (en) Macrocyclic hepatitis c serine protease inhibitors
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2007143694A3 (en) Macrocyclic oximyl hepatitis c protease inhibitors
WO2005037860A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005077969A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2009053828A3 (en) P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
MX2010006209A (es) Derivados de quinoxalinilo.
WO2009076173A3 (en) Fluorinated tripeptide hcv serine protease inhibitors
WO2008022006A3 (en) Arylalkoxyl hepatitis c virus protease inhibitors
WO2008021960A3 (en) Triazolyl macrocyclic hepatitis c serine protease inhibitors
WO2008019303A3 (en) Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
WO2008021956A3 (en) Acylaminoheteroaryl hepatitis c virus protease inhibitors
WO2005035525A3 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
MX2010005262A (es) Compuestos que contienen quinoxalina como inhibidores del virus de hepatitis c.
WO2008019289A3 (en) Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
ATE349463T1 (de) Verbrückte bizyklische serinproteaseinhibitoren
MX2010006518A (es) Inhibidores de serina proteasa de hepatitis c de oximil macrociclica.
MX2010010276A (es) Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c.
WO2009076166A3 (en) Oximyl hcv serine protease inhibitors